Shennon Biotechnologies

Shennon Biotechnologies is a biotechnology company developing a proprietary single-cell platform to accelerate the discovery of immunotherapy targets. Founded in 2021 by Dr. Li Sun and headquartered in San Francisco, the company aims to resolve a significant bottleneck in immunotherapy by enabling the functional profiling of millions of individual immune cells within hours. This high-throughput capability allows for the rapid identification of rare and effective T-cell receptors (TCRs) or antibody targets for the development of more precise treatments.

The company's core technology emerged from research initiated a decade prior at Harvard University. Founder and CEO Dr. Li Sun has a Ph.D. in Applied Physics from Harvard, where she focused on single-cell analysis in Dr. David Weitz's lab. Before establishing ShennonBio, she was a venture capitalist at Foundation Capital and Bessemer Venture Partners, evaluating deep-tech startups. This background in both science and venture capital underpins the company's strategy.

Shennon Biotechnologies' platform addresses the challenge of identifying antigen-specific immune cells, a process akin to finding a needle in a haystack, which traditionally takes weeks or months. By functionally analyzing millions of cells at once, ShennonBio can identify rare, functionally activated T cells and other targets in a single day. The company's business model involves using this platform to build a pipeline of effective targets. The initial focus is on developing cell therapies for solid tumors, with plans to expand into treating autoimmune diseases. The company forges collaborations with clinical centers and pharmaceutical partners to study patient samples and advance therapies toward clinical trials.

In March 2023, Shennon Biotechnologies announced it had raised $13 million in an oversubscribed seed funding round. The round was led by DCVC with participation from Foundation Capital, AV8, and angel investors. This capital is being used to expand the platform's capabilities and scale discovery efforts for its therapeutic pipeline.

Keywords: single-cell analysis, immunotherapy, T-cell receptors, TCR discovery, solid tumors, functional immune profiling, autoimmune diseases, cell therapy, antibody discovery, cancer immunotherapy, functional genomics, high-throughput screening, biotechnology, antigen interaction, drug discovery, life sciences, oncology, venture capital-backed